CoChat

Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis

Open access
Yashaswini, Chittampalli N., Qin, Tianyue, Bhattacharya, Dipankar, Amor, Corina, Lowe, Scott, Lujambio, Amaia, Wang, Shuang, Friedman, Scott L. · 2024 · Journal of Hepatology
Cited by 83

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background: Hepatic stellate cells (HSCs) are the key drivers of fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD), the fastest growing cause of hepatocellular carcinoma worldwide. HSCs are heterogenous, and a senescent subset of HSCs is implicated in hepatic fibrosis and HCC. Administration of anti-uPAR (urokinase-type plasminogen activator receptor) CAR T cells depletes senescent HSCs and attenuates fibrosis in murine liver injury models, including MASLD. However, the comprehensive features of senescent HSCs in MASLD, as well as their cellular ontogeny have not been characterized. Aims and Methods: Our aims were to comprehensively characterize and define the origin of senescent HSCs in human and murine MASLD by integrating senescence-associated beta galactosidase activity with immunostaining, flow cytometry and single nuclear RNA-sequencing (snRNAseq). We integrated the immunohistochemical profile with a senescence score applied to snRNAseq data to characterize senescent HSCs, and mapped the evolution of uPAR expression in MASLD. Results: Using pseudotime trajectory analysis, we establish that senescent HSCs arise from activated HSCs. While uPAR is expressed in MASLD, the magnitude and cell-specificity of its expression evolve with disease stage, such that in early disease, uPAR is more specific to activated and senescent HSCs, and in late disease, uPAR is also expressed by myeloid-lineage cells including Trem2+ macrophages and myeloid-derived suppressor cells. Furthermore, we identify novel surface proteins expressed on senescent HSCs in human and murine MASLD that could be exploited as therapeutic targets. Conclusions: These data define features of HSC senescence in human and murine MASLD, establishing an important blueprint to target these cells as part of future antifibrotic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2024.03.014

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Higashi, 2017, Hepatic stellate cells as key target in liver fibrosis, Adv Drug Deliv Rev, 121, 27, 10.1016/j.addr.2017.05.007 · DOI · Paper page
  2. Cogliati, 2023, Friend or foe? The elusive role of hepatic stellate cells in liver cancer, Nat Rev Gastroenterol Hepatol, 10.1038/s41575-023-00821-z · DOI · Paper page
  3. Pluquet, 2021, Cellular senescence and tumor promotion: role of the unfolded protein response, Adv Cancer Res, 150, 285, 10.1016/bs.acr.2021.01.001 · DOI
  4. Wagner, 2015, Overexpression of the novel senescence marker beta-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence, PLoS One, 10, 10.1371/journal.pone.0124366 · DOI · Paper page
  5. Li, 2020, FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome, Nat Cel Biol, 22, 728, 10.1038/s41556-020-0511-2 · DOI · Paper page
  6. Miyazoe, 2020, Extracellular vesicles from senescent hepatic stellate cells promote cell viability of hepatoma cells through increasing EGF secretion from differentiated THP-1 cells, Biomed Rep, 12, 163
  7. Raza, 2021, Current treatment paradigms and emerging therapies for NAFLD/NASH, Front Biosci (Landmark Ed), 26, 206, 10.2741/4892 · DOI · Paper page
  8. Hallsworth, 2019, Lifestyle modification in NAFLD/NASH: facts and figures, JHEP Rep, 1, 468, 10.1016/j.jhepr.2019.10.008 · DOI · Paper page
  9. Oseini, 2017, Therapies in non-alcoholic steatohepatitis (NASH), Liver Int, 37, 97, 10.1111/liv.13302 · DOI · Paper page
  10. Itahana, 2007, Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay, Methods Mol Biol, 371, 21, 10.1007/978-1-59745-361-5_3 · DOI · Paper page
  11. Kostallari, 2022, Stiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis, Am J Physiol Gastrointest Liver Physiol, 322, G234, 10.1152/ajpgi.00254.2021 · DOI · Paper page
  12. Regulski, 2017, Cellular senescence: what, why, and how, Wounds, 29, 168
  13. Thomas, 2003, PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification, Nucleic Acids Res, 31, 334, 10.1093/nar/gkg115 · DOI · Paper page
  14. Bolte, 2006, A guided tour into subcellular colocalization analysis in light microscopy, J Microsc, 224, 213, 10.1111/j.1365-2818.2006.01706.x · DOI · Paper page
  15. Jin, 2017, Hepatic stellate cell interferes with NK cell regulation of fibrogenesis via curcumin induced senescence of hepatic stellate cell, Cell Signal, 33, 79, 10.1016/j.cellsig.2017.02.006 · DOI
  16. Yang, 2021, Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice, Hepatology, 74, 2774, 10.1002/hep.31987 · DOI · Paper page
  17. Zhang, 2021, Heterogeneity of hepatic stellate cells in fibrogenesis of the liver: insights from single-cell transcriptomic analysis in liver injury, Cells, 10, 10.3390/cells10082129 · DOI
  18. Zisser, 2021, Hepatic stellate cell activation and inactivation in NASH-fibrosis-roles as putative treatment targets?, Biomedicines, 9, 10.3390/biomedicines9040365 · DOI · Paper page
  19. Su, 2021, Single-cell RNA transcriptome landscape of hepatocytes and non-parenchymal cells in healthy and NAFLD mouse liver, iScience, 24, 10.1016/j.isci.2021.103233 · DOI · Paper page
  20. Zhu, 2023, CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor, Cell Discov, 9, 25, 10.1038/s41421-023-00529-z · DOI · Paper page
  21. Xi, 2021, Protocol for executing and benchmarking eight computational doublet-detection methods in single-cell RNA sequencing data analysis, STAR Protoc, 2
  22. Dal-Secco, 2015, A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury, J Exp Med, 212, 447, 10.1084/jem.20141539 · DOI · Paper page
  23. Choe, 2021, SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma, Sci Transl Med, 13, 10.1126/scitranslmed.abe7378 · DOI · Paper page
  24. Tousley, 2023, Co-opting signalling molecules enables logic-gated control of CAR T cells, Nature, 615, 507, 10.1038/s41586-023-05778-2 · DOI · Paper page
  25. Haque, 2019, CD206(+) tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production, Sci Rep, 9, 10.1038/s41598-019-51149-1 · DOI
  26. Guo, 2017, M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma, Oncotarget, 8, 44465, 10.18632/oncotarget.17973 · DOI · Paper page
  27. Bruna, 2021, Pro-tumorigenic macrophage infiltration in oral squamous cell carcinoma and possible macrophage-aimed therapeutic interventions, Front Oncol, 11, 10.3389/fonc.2021.675664 · DOI

Cited by

See all 83

Metadata

Authors
Yashaswini, C. N., Qin, T., Bhattacharya, D., Amor, C., Lowe, S., Lujambio, A., Wang, S., & Friedman, S. L.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2024-08
Volume
81
Issue
2
Pages
207-217
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4392930808
Cited by
83
References
32
FWCI
18.55
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • National Center for Advancing Translational Sciences
  • National Institutes of Health (P30CA045508, S10OD026880, S10OD030463)
  • Icahn School of Medicine at Mount Sinai (UL1TR004419)
  • American Gastroenterological Association Research Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.